52 related articles for article (PubMed ID: 16900736)
1. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Wang X; Li M; Zeng X; Wang Q
Rheumatology (Oxford); 2023 Oct; 62(10):e293-e294. PubMed ID: 36943383
[No Abstract] [Full Text] [Related]
4. Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog.
da Silva MES; Christianetti B; Amazonas E; Pereira ML
Front Vet Sci; 2024; 11():1309167. PubMed ID: 38406630
[TBL] [Abstract][Full Text] [Related]
5. Discoid lupus erythematosus of the nail treated with thalidomide.
Harp T; Woodbury MJ; Merola JF
JAAD Case Rep; 2023 Oct; 40():106-108. PubMed ID: 37771355
[No Abstract] [Full Text] [Related]
6. Secondary amenorrhea in a β-thalassemia major patient treated with thalidomide.
Yu Y; Yang K
Pediatr Blood Cancer; 2024 Jun; 71(6):e30982. PubMed ID: 38526227
[No Abstract] [Full Text] [Related]
7. Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms.
Domingo S; Solé C; Moliné T; Ferrer B; Ordi-Ros J; Cortés-Hernández J
Dermatology; 2020; 236(5):467-476. PubMed ID: 32659758
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Chasset F; Tounsi T; Cesbron E; Barbaud A; Francès C; Arnaud L
J Am Acad Dermatol; 2018 Feb; 78(2):342-350.e4. PubMed ID: 28989111
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy.
Ordi-Ros J; Cortés F; Cucurull E; Mauri M; Buján S; Vilardell M
J Rheumatol; 2000 Jun; 27(6):1429-33. PubMed ID: 10852265
[TBL] [Abstract][Full Text] [Related]
11. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
Thomson KF; Goodfield MJ
J Dermatolog Treat; 2001 Sep; 12(3):145-7. PubMed ID: 12243705
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.
Gambini D; Carrera C; Passoni E; Muratori S; Berti E; Caputo R
J Dermatolog Treat; 2004 Dec; 15(6):365-71. PubMed ID: 15764048
[TBL] [Abstract][Full Text] [Related]
14. [Thalidomide therapy for discoid lupus erythematosus].
Lyakhovisky A; Baum S; Shpiro D; Salomon M; Trau H
Harefuah; 2006 Jul; 145(7):489-92, 551. PubMed ID: 16900736
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
